Monday, June 6, 2022, Chicago, Illinois, 7:00 PM – 9:30 PM Central Time (8:00 PM – 10:30 PM Eastern Time)

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Breast Cancer

A CME Hybrid Symposium Held in Conjunction with the 2022 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:30 PM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Javier Cortés, MD, PhD
Head, IBCC International Breast Cancer Center
Barcelona, Spain

Matthew P Goetz, MD
Erivan K Haub Family Professor of Cancer Research
Honoring Richard F Emslander, MD
Professor of Oncology and Pharmacology
Director, Mayo Clinic Breast SPORE
Co-Leader, Women’s Cancer Program
Chair, Breast Cancer Research Committee
Vice Chair, Academic and Community Research United (ACCRU)
Mayo Clinic
Rochester, Minnesota

Erika Hamilton, MD
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee

Ian E Krop, MD, PhD
Associate Director, Clinical Research
Director, Clinical Trials Office
Chief Clinical Research Officer
Yale Cancer Center
New Haven, Connecticut


Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Sara M Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director, Susan F Smith Center for Women's Cancers
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences, Gilead Sciences Inc, Lilly, Merck, Puma Biotechnology Inc, Sanofi Genzyme, and Seagen Inc.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:30 PM — Educational Meeting

MODULE 1: Optimizing the Management of ER-Positive Localized Breast Cancer

  • Optimal selection and duration of adjuvant therapy for premenopausal and postmenopausal patients with ER-positive, HER2-negative localized breast cancer; clinicopathologic factors affecting the decision to consult a genomic classifier
  • Major clinical findings from the Phase III RxPONDER trial evaluating the role of chemotherapy for premenopausal and postmenopausal patients with ER-positive, HER2-negative localized breast cancer with 1 to 3 positive lymph nodes and a 21-gene Recurrence Score® of ≤25
  • Other recent data sets informing the use of genomic assays to guide neoadjuvant and adjuvant treatment decision-making
  • Key efficacy and safety outcomes observed in the Phase III monarchE trial with the addition of abemaciclib to standard adjuvant hormonal therapy for patients with ER-positive, HER2-negative breast cancer at high risk for recurrence
  • FDA approval of adjuvant abemaciclib and identification of appropriate patients for this strategy
  • Other ongoing studies (eg, NATALEE, eMonarcHER) evaluating CDK4/6 inhibitors for localized ER-positive breast cancer

MODULE 2: New and Novel Treatment Strategies for Localized Triple-Negative Breast Cancer (TNBC)

  • Clinical and biologic rationale for the investigation of PARP inhibition and immune checkpoint blockade in localized breast cancer
  • Available data from the Phase III KEYNOTE-522 study demonstrating an event-free survival advantage with neoadjuvant pembrolizumab combined with chemotherapy and continued as a single agent after surgery for high-risk localized TNBC
  • FDA approval of (neo)adjuvant pembrolizumab; patient selection and practical implementation
  • Design, eligibility criteria and key efficacy and safety findings from the Phase III OlympiA trial assessing adjuvant olaparib for patients with germline BRCA1/2 mutations and high-risk HER2-negative breast cancer
  • Recent FDA approval of adjuvant olaparib and implications of the OlympiA trial results for genetic testing and patient selection for this strategy
  • Available data with and ongoing clinical research evaluating other PARP inhibitors or immune checkpoint inhibitors as a component of neoadjuvant or adjuvant therapy for localized TNBC

MODULE 3: Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer

  • Clinical factors affecting the decision to administer neoadjuvant systemic treatment to patients with HER2-positive localized breast cancer; selecting a neoadjuvant regimen
  • Available data (eg, ADAPT HR+/HER2-, TRAIN-2, TRAIN-3) exploring the feasibility of chemotherapy de-escalation in the setting of dual HER2 blockade for patients with localized disease
  • Key data supporting the use of adjuvant T-DM1 for HER2-positive breast cancer; current nonresearch role, if any, for patients beyond those with residual disease after neoadjuvant therapy
  • Patient selection for and clinical factors guiding the use of neratinib as extended-adjuvant therapy; improvement in rates of CNS recurrence observed after long-term follow-up of the Phase III ExteNET study
  • Dose escalation and other available strategies to reduce the toxicities associated with postadjuvant neratinib
  • Ongoing clinical trials (eg, DESTINY-Breast05, CompassHER2 RD, MARGOT) investigating HER2-targeted strategies for HER2-positive localized breast cancer

MODULE 4: Evolving Clinical Decision-Making for Patients with HER2-Positive Metastatic Breast Cancer (mBC)

  • Clinical factors in the selection and sequencing of therapy for patients with HER2-positive mBC; role of rechallenge with anti-HER2 therapies received in the (neo)adjuvant setting
  • Published data from the pivotal HER2CLIMB, DESTINY-Breast01, NALA and SOPHIA studies of tucatinib/trastuzumab/capecitabine, T-DXd, neratinib/capecitabine and margetuximab/chemotherapy, respectively, for HER2-positive mBC
  • Optimal integration of tucatinib/trastuzumab/capecitabine, T-DXd, neratinib/capecitabine and margetuximab/chemotherapy into therapy for patients with and without brain metastases
  • Key efficacy and safety findings from the Phase III DESTINY-Breast03 trial evaluating T-DXd versus T-DM1 for patients with HER2-positive mBC previously treated with trastuzumab and a taxane; implications for therapeutic sequencing
  • Biologic rationale for, early data with and ongoing evaluation of T-DXd for HER2-low breast cancer
  • Ongoing clinical research evaluating novel HER2-targeted strategies for HER2-positive mBC

MODULE 5: Selection and Sequencing of Therapy for ER-Positive, HER2-Negative mBC

  • Long-term follow-up data, including overall survival findings, with CDK4/6 inhibitors for patients with ER-positive mBC; factors in the selection of a CDK4/6 inhibitor and an endocrine partner for first-line treatment
  • Design, eligibility criteria and key endpoints of the Phase III HARMONIA trial comparing ribociclib to palbociclib, each in combination with endocrine therapy, for patients with HR-positive, HER2-negative mBC of a HER2-enriched intrinsic subtype
  • Proposed mechanisms of resistance to CDK4/6 inhibition; ongoing clinical trials (eg, PACE, MAINTAIN, PALMIRA) assessing CDK4/6 inhibitor retreatment after disease progression on prior CDK4/6 inhibitor therapy
  • Published research findings with alpelisib/fulvestrant in patients with ER-positive mBC and PIK3CA mutations; optimal incorporation into current management algorithms
  • Mechanisms of action of next-generation SERDs (eg, amcenestrant, elacestrant); available and emerging data and ongoing evaluation for patients with ER-positive, HER2-negative mBC
  • Other novel agents and strategies under investigation for ER-positive mBC (eg, capivasertib, patritumab deruxtecan, sacituzumab govitecan, FGFR inhibitors)

MODULE 6: Recent Advances in the Care of Patients with Metastatic TNBC (mTNBC)

  • Phase III data sets evaluating anti-PD-1/PD-L1 antibodies in combination with chemotherapy for previously untreated PD-L1-positive mTNBC; current role in clinical practice
  • Clinical implications of the recent voluntary withdrawal of the first-line indication for atezolizumab with nab paclitaxel for mTNBC
  • Key clinical research findings guiding the optimal use of PARP inhibitors for mTNBC
  • Key efficacy and safety findings from the Phase III ASCENT trial comparing sacituzumab govitecan to physician’s choice of chemotherapy for relapsed/refractory mTNBC; optimal integration of sacituzumab govitecan into clinical practice
  • Other antibody-drug conjugates under investigation for mTNBC (eg, T-DXd, ladiratuzumab vedotin, datopotamab deruxtecan)
  • Available data with and ongoing investigation of other promising novel agents and strategies (eg, lenvatinib/pembrolizumab) for patients with advanced TNBC

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Evaluate published research data to guide the selection and duration of neoadjuvant, adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Implement a long-term clinical plan for the care of patients with metastatic HER2-positive breast cancer, incorporating current and recently approved anti-HER2 therapies.
  • Recognize common and rare side effects associated with novel anti-HER2 agents, and use this information to develop supportive management plans for patients undergoing treatment for HER2-positive breast cancer.
  • Evaluate the results of genomic assays and other patient and treatment-related factors to personalize adjuvant systemic therapy for newly diagnosed ER-positive breast cancer.
  • Consider available clinical trial findings with CDK4/6 inhibitors for localized ER-positive, HER2-negative breast cancer, and assess the optimal role of these agents as a component of adjuvant treatment.
  • Individualize the selection and sequencing of systemic therapy for patients with ER-positive metastatic breast cancer.
  • Review published data supporting the benefit of chemotherapy in combination with anti-PD-1/PD-L1 antibodies for localized or metastatic triple-negative breast cancer (TNBC), and use this information to make treatment recommendations for patients.
  • Evaluate published research findings guiding the selection and sequencing of available therapeutic agents for patients with PD-L1-negative TNBC or those who experience disease progression on front-line chemoimmunotherapy.
  • Appraise efficacy and safety data with PARP inhibitors for patients with localized and metastatic breast cancer and BRCA1/2 mutations, and consider the diagnostic and therapeutic implications.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr CortésConsulting Agreements: AstraZeneca Pharmaceuticals LP, Athenex, BioInvent, Bioasis Technologies Inc, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Cellestia, Clovis Oncology, Daiichi Sankyo Inc, Ellipses Pharma, Erytech Pharma, GEMoaB Monoclonals, Gilead Sciences Inc, GlaxoSmithKline, HiberCell, Leuko Labs Inc, Lilly, Menarini Group, Merck Sharp & Dohme LLC, Polyphor, Reveal Genomics, Roche Laboratories Inc, Seagen Inc, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Baxalta GmbH, Bayer HealthCare Pharmaceuticals, Eisai Inc, F Hoffmann-La Roche Ltd, Guardant Health, Merck Sharp & Dohme LLC, Pfizer Inc, PIQUR Therapeutics, Puma Biotechnology Inc, Queen Mary University of London, Roche Laboratories Inc, Servier Affaires Medicales, Takeda Pharmaceuticals USA Inc; Honoraria: Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Lilly, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Roche Laboratories Inc, Samsung Bioepis; Patents: WO 2014/199294 A, US 2019/ 0338368 A1; Stock: MEDSIR, Nektar, Leuko Labs Inc (stock owned by relative); Travel, Accommodation, Expenses: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Gilead Sciences Inc, Novartis, Pfizer Inc, Roche Laboratories Inc. Dr GoetzConsulting Agreements (Honoraria to institution): ARC Therapeutics, AstraZeneca Pharmaceuticals LP, Biovica, bioTheranostics Inc, Blueprint Medicines, Eagle Pharmaceuticals, Lilly, Novartis, Pfizer Inc, Sanofi Genzyme, Sermonix Pharmaceuticals; Contracted Research (To Institution): Lilly, Pfizer Inc, Sermonix Pharmaceuticals. Dr HamiltonConsulting Agreements (Paid to Institution): Arcus Biosciences,Arvinas, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Deciphera Pharmaceuticals Inc, Eisai Inc, Genentech, a member of the Roche Group, Greenwich LifeSciences Inc, H3 Biomedicine, iTeos Therapeutics, Janssen Biotech Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Novartis, Orum Therapeutics, Pfizer Inc, Puma Biotechnology Inc, Relay Therapeutics, Seagen Inc, Silverback Therapeutics; Contracted Research (Paid to Institution): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics, Akesobio Australia Pty Ltd, Amgen Inc, ArQule Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Compugen, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dana-Farber Cancer Institute, Deciphera Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, Ellipses Pharma, EMD Serono Inc, Fochon Pharmaceuticals Ltd, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Harpoon Therapeutics, Hutchison MediPharma, ImmunoGen Inc, Immunomedics Inc, Incyte Corporation, InventisBio, Jacobio Pharmaceuticals Group Co Ltd, Karyopharm Therapeutics, Leap Therapeutics Inc, Lilly, Lycera, MacroGenics Inc, Marker Therapeutics Inc, Merck, Mersana Therapeutics Inc, Merus BV, Molecular Templates, Myriad Genetic Laboratories Inc, Novartis, NuCana, Olema Oncology, OncoMed Pharmaceuticals Inc, Onconova Therapeutics Inc, ORIC Pharmaceuticals Inc, Orinove Inc, Pfizer Inc, PharmaMar, Pieris Pharmaceuticals Inc, Pionyr Immunotherapeutics, Plexxikon Inc, Puma Biotechnology Inc, Radius Health Inc, Regeneron Pharmaceuticals Inc, Repertoire Immune Medicines, Rgenix, Seagen Inc, Sermonix Pharmaceuticals, Shattuck Labs, Silverback Therapeutics, Stemcentrx, Sutro Biopharma, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Transcenta Holding Ltd, Treadwell Therapeutics, Verastem Inc, Vincerx Pharma, Zenith Epigenetics, Zymeworks Inc. Dr KropConsulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, MacroGenics Inc, Seagen Inc, Taiho Oncology Inc; Contracted Research (Clinical Trial Support Paid to Institution): Genentech, a member of the Roche Group, MacroGenics Inc, Pfizer Inc. Dr RugoConsulting Agreement: Samsung Bioepis (limited consulting); Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Odonate Therapeutics, Pfizer Inc, Seagen Inc, Sermonix Pharmaceuticals; Honoraria: Mylan, Puma Biotechnology Inc; Travel: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, MacroGenics Inc, Merck, Mylan, Novartis, Pfizer Inc. Dr TolaneyConsulting Agreements: 4D Pharma PLC, AstraZeneca Pharmaceuticals LP, Athenex, BeyondSpring Pharmaceuticals Inc, Bristol-Myers Squibb Company, Certara, Chugai Pharmaceutical Co Ltd, CytomX Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Infinity Pharmaceuticals Inc, Kyowa Kirin Co Ltd, Lilly, Merck, Mersana Therapeutics Inc, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, OncoPep, OncoSec Medical, OncXerna Therapeutics Inc, Pfizer Inc, Puma Biotechnology Inc, Samsung Bioepis, Sanofi Genzyme, Seagen Inc, Zentalis Pharmaceuticals, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, Pfizer Inc, Sanofi Genzyme, Seagen Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences, Gilead Sciences Inc, Lilly, Merck, Puma Biotechnology Inc, Sanofi Genzyme, and Seagen Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

Directions:
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of breast cancer.

There is no fee to participate in this program or live webcast of this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

Registration for in-person meeting

In order to attend this in-person event, please register here.

Registration for event »
 
Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.